Free Trial

Cidara Therapeutics (CDTX) Stock Price, News & Analysis

Cidara Therapeutics logo
$65.47 -1.49 (-2.22%)
Closing price 03:58 PM Eastern
Extended Trading
$65.45 -0.02 (-0.04%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cidara Therapeutics Stock (NASDAQ:CDTX)

Key Stats

Today's Range
$64.97
$66.90
50-Day Range
$21.02
$67.49
52-Week Range
$10.14
$69.36
Volume
130,393 shs
Average Volume
380,402 shs
Market Capitalization
$1.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.14
Consensus Rating
Buy

Company Overview

Cidara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

CDTX MarketRank™: 

Cidara Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 280th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cidara Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cidara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cidara Therapeutics are expected to decrease in the coming year, from ($8.74) to ($14.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cidara Therapeutics is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cidara Therapeutics is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cidara Therapeutics has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cidara Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.92% of the float of Cidara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cidara Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cidara Therapeutics has recently decreased by 3.52%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cidara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cidara Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.92% of the float of Cidara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cidara Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cidara Therapeutics has recently decreased by 3.52%, indicating that investor sentiment is improving.
  • News Sentiment

    Cidara Therapeutics has a news sentiment score of 1.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Cidara Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 8 people have searched for CDTX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cidara Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,999,988.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 7.64% of the stock of Cidara Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 35.82% of the stock of Cidara Therapeutics is held by institutions.

  • Read more about Cidara Therapeutics' insider trading history.
Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CDTX Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
Cidara Therapeutics (CDTX) Receives a Buy from Needham
See More Headlines

CDTX Stock Analysis - Frequently Asked Questions

Cidara Therapeutics' stock was trading at $26.88 at the beginning of the year. Since then, CDTX stock has increased by 143.6% and is now trading at $65.4750.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its quarterly earnings data on Thursday, August, 7th. The biotechnology company reported ($1.65) EPS for the quarter, beating the consensus estimate of ($1.87) by $0.22.
Read the conference call transcript
.

Cidara Therapeutics's stock reverse split on the morning of Wednesday, April 24th 2024.The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Cidara Therapeutics (CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Cidara Therapeutics' top institutional investors include Bain Capital Life Sciences Investors LLC (9.86%), Vivo Capital LLC (5.17%), Commodore Capital LP (4.63%) and Adage Capital Partners GP L.L.C. (4.34%). Insiders that own company stock include Ra Capital Management, LP, Jeffrey Stein, Taylor Sandison, Leslie Tari, Shane Ward, Preetam Shah and Paul Daruwala.
View institutional ownership trends
.

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include Meta Platforms (META), VBI Vaccines (VBIV), SCYNEXIS (SCYX), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
8/07/2025
Today
8/27/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CDTX
CIK
1610618
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

High Price Target
$75.00
Low Price Target
$45.00
Potential Upside/Downside
-4.2%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($11.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$169.83 million
Net Margins
N/A
Pretax Margin
-61,454.97%
Return on Equity
-50.81%
Return on Assets
-42.46%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.45
Quick Ratio
16.45

Sales & Book Value

Annual Sales
$1.27 million
Price / Sales
1,337.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$19.76 per share
Price / Book
3.39

Miscellaneous

Outstanding Shares
25,360,000
Free Float
23,421,000
Market Cap
$1.70 billion
Optionable
No Data
Beta
1.18

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:CDTX) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners